2014.05.15. INV-17 ROR gamma inhibitor portfolio in preclinical development stage

Written by Adam Parks

INV-17 Preclinical Development in Multiple Autoimmune Diseases Profiled in SciBx Distillery: Therapeutics

Read Here +

Adam Parks https://apollocreativeco.com
Previous

2014.07.25. Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its oral NCE INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases
Next

2014.02.17. INV-17 ROR gamma Autoimmune Disease Preclinical POC